Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications | 2 Mers Seas Zeeën

IMODE

Vous êtes ici

Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

Lead partner

University Lille 1 - Unité Matériaux et Transformations

Contact

Date de début

01/07/2016

Date de fin

30/06/2021

Project budget

5 960 060

ERDF amount

3 576 036

ERDF rate

60%

    À propos

    Common challenge

    The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel medicines while maintaining low medical costs. This will be achieved with the collaboration of academic research groups and SMEs through a transdisciplinary applied research programme in materials science, pharmacy, biology and medicine. The project will strengthen innovation in the 2 Seas Area in order to obtain a strategic advantage for novel pharmaceutical and medical applications bridging the current gap between academia and the private sector.

    Main Achievements

    The objective of IMODE is to enhance R&D on major societal challenges for improved healthcare by developing solutions for novel pharmaceutical products and medical devices through new multicomponent drug systems. It is based on the international joint collaboration between academic research groups, 2 SMEs, one large company and one economic development agency.
    The project has started on 1 July 2016 and will end on 30 June 2021. It has obtained two 6-month extensions in 2020 (one requested and one automatically granted because of the Covid-19)

    Based on a rich and fruitful cross border cooperation, many remarkable achievements have been obtained in three categories:

    1/ New Materials & Formulations with improved properties (solubility, stability, efficacy, robustness):

    • 6 novel pharmaceutical cocrystals
    • 1 new non-viral hybrid polysaccharide nanogel for gene delivery
    • 1 new thin polymeric film for “colon targeting” drug
    • 1 new bio-based excipient for controlled release

    2/ New Processing Technologies, Protocols & Methodologies:

    • 2 new processes for efficient pharmaceutical cocrystals synthesis
    • 1 smarter protocol to improve the dissolution rate of poorly water soluble drugs in a polymer matrix
    • 1 faster methodology to determine the complex phase diagramme of drugs dispersed in polymer matrices
    • 2 new experimental/numerical techniques for faster cocrystals screening

    3/ New Medical Devices: 2 new stents for the treatment of coronary artery diseases including in vivo/in vitro texts and exome analysis

    Practically, all activities have generated:

    • 22 scientific publications in high impact factor journals
    • 39 oral presentations at prestigious international conferences
    • 4 patents filed + 2 “Invention disclosure” submitted
    • 6 conventions ( 1 x Greenwich, 4 x Lille BIOFIT&MEDFIT, 1x Marseille BIOFIT) including participants from academia and companies
    • A "mutlitude" of B2B meetings between academics and companies
    • 1 Final Event organized online in the framework of BIOFIT(Dec 2020, Lille)
    • 2 training schools (University of East-Anglia &University of Lille 2018)
    • 11 PhDs trained

    The IMODE partnership has also strongly contributed to obtain the Erasmus+ Joint Master BIOPHAM "Bio&Pharmaceutial Materials Science"

    8 Outputs over the expected 9 Outputs have been already delivered. 1 Output related to WP2 "Innovative medical devices" has been significantly delayed because of the Covid-19 but will be delivered before the end of the project.

    Partnership

    Partners

    University College London, UCL School of Pharmacy

    Université Lille 2 Droit et Santé

    Universiteit Gent Laboratory of Pharmaceutical Technology

    University of East Anglia

    ImaBiotech

    University of Greenwich

    G.I.E Eurasanté

    Ashford and St Peter's Hospital's NHS Foundation Trust

    Cubic Pharmaceuticals Limited

    Roquette Frères

    Outputs

    Theme
    Type
    Target
    URL / Download
    30/09/2019

    Prototypes of the technique for offline preformulation screening and inline process optimisation analysis (TRL5)

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Design of new drug-drug compound combinations (TRL5). 

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Development of innovative tech. for materials formulation (TRL4)

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Stability- enhanced hot-melt extruded co-amorphous solid dispersion (TRL4). 

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    31/12/2019

    Bio-based matrix solid dosage form for oral controlled drug delivery (TRL5). 

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Advanced drug delivery systems for colon targeting (TRL4)

    Thème: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises